A Clinical Stage, Next Generation Immune therapy to Combat Cancer

download our presentation
Title slide of a scientific presentation titled 'Development of SR-8541A: our novel ENPP1 inhibitor'. The slide explains that SR-8541A was designed to potently and selectively inhibit ENPP1, allow activation of the innate immune system, enhance adaptive immune therapies, synergize with standard care therapies like chemo and radiation, and provide a safer alternative for innate immune activation.

Grants and Awards

Logo of the National Institutes of Health, with a blue background and text about cancer prevention and research at the Texas Cancer Prevention & Research Institute.

“It’s Our Revolutionary Approach That Enables The Full Immune System To Fight back against Cancer.”

- JON NORTHRUP, CEO

 
 

To learn more, or schedule a meeting, fill out the form and one of our team members will respond shortly.

back to top